|Bid||62.55 x 1200|
|Ask||63.79 x 1000|
|Day's Range||60.41 - 64.00|
|52 Week Range||42.51 - 155.87|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||16.53|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
The leading gene editing company CRISPR Therapeutics is looking better to technically oriented traders. Let's take a look. In this daily bar chart of CRSP, below, we can see that following a downtrend that prices have turned sideways since January.
Vaxart (NASDAQ: VXRT) is working on a coronavirus vaccine candidate. Recently, Vaxart said its omicron-specific candidate and its original candidate both protected against the variant in preclinical tests. Of course, even if Vaxart is successful, the company will make it to market much later than bigger rivals.
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.